2011

• Leal, T., Remick, S., Takimoto, C., Ramanathan, R., Davies, A., Egorin, M., Hamilton, A., Lorusso, P., Shibata, S., Lenz, H., Mier, J., Sarantopoulos, J., Mani, S., Wright, J., Ivy, S., Neuwirth, R., von Moltke, L., Venkatakrishnan, K., Mulkerin, D. (2011), Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. Cancer chemotherapy and pharmacology. 68(6), 1439-47. [Abstract]
• Long, G., Menzies, A., Nagrial, A., Haydu, L., Hamilton, A., Mann, G., Hughes, T., Thompson, J., Scolyer, R., Kefford, R. (2011), Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(10), 1239-46. [Abstract]

2010

• Ocean, A., Polite, B., Christos, P., Horvath, L., Hamilton, A., Matulich, D., Chen, H., Sparano, J., Kindler, H. (2010), Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma. Clinical Colorectal Cancer. 9(5), 290-296. [Abstract]
• Handolias, D., Hamilton, A., Salemi, R., Tan, A., Moodie, K., Kerr, L., Dobrovic, A., McArthur, G. (2010), Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. British Journal of Cancer. 102(8), 1219-2123. [Abstract]
• Zardawi, S., Zardawi, I., McNeil, C., Millar, E., McLeod, D., Morey, A., Crea, P., Murphy, N., Pinese, M., Lopez-Knowles, E., Oakes, S., Ormandy, C., Qiu, M., Hamilton, A., Spillane, A., Soon Lee, C., Sutherland, R., Musgrove, E., O'Toole, S. (2010), High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtype. Histopathology. 56(3), 286-296. [Abstract]
• Ott, P., Hamilton, A., Jones, A., Haas, N., Shore, T., Liddell, S., Christos, P., Doyle, L., Millward, M., Muggia, F., Pavlick, A. (2010), A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma. PloS one. 5(1), e8714. [Abstract]
• Eisen, T., Trefzer, U., Hamilton, A., Hersey, P., Millward, M., Knight, R., Jungnelius, J., Glaspy, J. (2010), Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer. 116(1), 146-154. [Abstract]
• Ott, P., Hamilton, A., Min, C., Safarzadeh-Amiri, S., Goldberg, L., Yoon, J., Yee, H., Buckley, M., Christos, P., Wright, J., Polsky, D., Osman, I., Liebes, L., Pavlick, A. (2010), A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PloS One. 5(12), e15588. [Abstract]

2009

• Pavlick, A., Wu, J., Roberts, J., Rosenthal, M., Hamilton, A., Wadler, S., Farrell, K., Carr, M., Fry, D., Murgo, A., Oratz, R., Hochster, H., Liebes, L., Muggia, F. (2009), Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors. Cancer Chemotherapy and Pharmacology. 64(4), 803-810. [Abstract]
• Goel, S., Sharma, R., Hamilton, A., Beith, J. (2009), LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database of Systematic Reviews. 4(4), CD004562. [Abstract]

2008

• Clark, K., Hamilton, A. (2008), Melanoma. In: Prognosis in Advanced Cancer. (pp.257-265).United States: Oxford University Press.
• Sharma, R., Hamilton, A., Beith, J. (2008), LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane database of systematic reviews. 4(4), CD004562. [Abstract]